clinical trial · NCT07172516
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Bipolar DisorderBipolar DepressionBipolar I DisorderBipolar II DisorderAzetukalnerPlacebo
brief summary
X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).
started
Aug 8, 2025
primary completion
Jun 1, 2028
completion
Aug 1, 2028
last updated
Apr 1, 2026
official title
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol